Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.37 |
| ▸ | TUBB | P07437 | 2/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033989 | 0.91 | LMNA (0.39) | PKN1PKN2JAK2PARP1TGFBR1 | |
| SCHEMBL2052779 | 0.87 | PLK4 (0.44) | PKN1PKN2JAK2PARP1TUBB4A | |
| SCHEMBL2053135 | 0.87 | SMN1; SMN2 (0.43) | ICAM1SELEPARP1TGFBR1PTGS2 | |
| SCHEMBL4035973 | 0.86 | KDM4E (0.45) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2053003 | 0.86 | PTGS2 (0.40) | JAK2PARP1TGFBR1CDC7TGFBR2 | |
| SCHEMBL2049205 | 0.86 | PNP (0.39) | PKN1PKN2JAK2PARP1TGFBR1 | |
| SCHEMBL2053600 | 0.85 | JAK2 (0.52) | PKN1PKN2JAK2PARP1TUBB4A | |
| SCHEMBL2052754 | 0.85 | TUBB4A (0.44) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4043268 | 0.83 | PKN1 (0.36) | ICAM1SELEPKN1PKN2JAK2 | |
| SCHEMBL2050384 | 0.83 | PARP1 (0.45) | PARP1TGFBR1GRM4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4691506-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-7402672-B2 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | claimed |
| EP-1747220-A1 | SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | Aventis Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005061498-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | claimed |
| US-7626027-B2 | Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase Iε | AVENTIS PHARMACEUTICALS INC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | AVENTIS PHARMACEUTICALS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7402672-B2 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1747220-A1 | SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | Aventis Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005061498-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | CSNK1E, CSNK1G3, CSNK2A3 | ICAM1 4266/4885SELE 4751/4885PKN1 69/4885 |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | CSNK2A3, PACSIN2, CSNK1G3 | ICAM1 4837/4885SELE 4809/4885PKN1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.